CancerDrs

Prostate Cancer clinical trials in Connecticut

21 actively recruiting prostate cancer trials at 8 sites across Connecticut.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full prostate cancer transparency page →

Phase 3 Recruiting Network

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Connecticut:
  • Veterans Affairs Connecticut Healthcare System-West Haven Campus — West Haven, Connecticut
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Connecticut:
  • Smilow Cancer Hospital Care Center - Guilford — Guilford, Connecticut
  • Yale University — New Haven, Connecticut
  • Stamford Hospital/Bennett Cancer Center — Stamford, Connecticut
  • Smilow Cancer Hospital Care Center-Trumbull — Trumbull, Connecticut
  • Smilow Cancer Hospital Care Center - Waterford — Waterford, Connecticut
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 wit…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in Connecticut:
  • Hartford Hospital — Hartford, Connecticut
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06925737
Sites in Connecticut:
  • Yale-New Haven Hospital-Yale Cancer Center ( Site 0050) — New Haven, Connecticut
  • Veterans Affairs Connecticut Healthcare System ( Site 0062) — West Haven, Connecticut
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Connecticut:
  • Yale-New Haven Hospital-Yale Cancer Center ( Site 0064) — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).

Sponsor: Amgen
NCT ID: NCT07213674
Sites in Connecticut:
  • Hartford HealthCare Cancer Institute at Hartford Hospital — Hartford, Connecticut
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632977
Sites in Connecticut:
  • Stamford Hospital/Bennett Cancer Center — Stamford, Connecticut
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03972657
Sites in Connecticut:
  • Yale University Hospital — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other…

Sponsor: Pfizer
NCT ID: NCT04606446
Sites in Connecticut:
  • Smilow Cancer Hospital at Yale - New Haven — New Haven, Connecticut
  • Yale-New Haven Hospital- Yale Cancer Center — New Haven, Connecticut
  • Smilow Cancer Hospital Phase 1 Unit — New Haven, Connecticut
  • Yale University — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06800313
Sites in Connecticut:
  • Yale University — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a m…

Sponsor: Phanes Therapeutics
NCT ID: NCT05652686
Sites in Connecticut:
  • Yale University Cancer Center — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expan…

Sponsor: GlaxoSmithKline
NCT ID: NCT06990880
Sites in Connecticut:
  • GSK Investigational Site — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

The SUGAR Study; SBRT and Relugolix) for Prostate Cancer

The goal of this clinical trial is to measure the toxicity and effectiveness of the following treatments for cFIR/cgUIR prostate cancer patients. Stereotactic body radiotherapy (SBRT) alone or Stereotactic body radiotherapy (SBRT) combined…

Sponsor: Yale University
NCT ID: NCT06111781
Sites in Connecticut:
  • Yale Cancer Center — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Connecticut:
  • Exelixis Clinical Site #62 — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant p…

Sponsor: Janux Therapeutics
NCT ID: NCT05519449
Sites in Connecticut:
  • Yale New Haven Hospital — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms

Sponsor: SystImmune Inc.
NCT ID: NCT07080242
Sites in Connecticut:
  • Yale Cancer Center — New Haven, Connecticut
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Connecticut:
  • Massive Bio SYNERGY-AI site — Hartford, Connecticut
  • Massive Bio SYNERGY-AI site — Norwalk, Connecticut
View on ClinicalTrials.gov →
Recruiting Academic/Other

International Registry for Men With Advanced Prostate Cancer (IRONMAN)

Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 C…

Sponsor: Prostate Cancer Clinical Trials Consortium
NCT ID: NCT03151629
Sites in Connecticut:
  • Yale University — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 4 Recruiting Industry

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred t…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05803941
Sites in Connecticut:
  • Hartford Hospital — Hartford, Connecticut
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12